20 FL X CERTIFIED DESIGNATED
REPRESENTATIVE EXAM (FLORIDA
BOARD OF PHARMACY – DESIGNATED
REPRESENTATIVE FOR PRESCRIPTION
DRUG DISTRIBUTORS ACTUAL EXAM
Certified Designated Representative (DR) – Florida
Prescription Drug Distributor Exam
The Florida Board of Pharmacy Certified Designated
Representative (DR) for Prescription Drug Distributors
examination evaluates competency in pharmaceutical
wholesale distribution compliance, focusing on federal and
Florida laws governing the safe storage, handling,
tracking, and distribution of prescription drugs. It
emphasizes regulatory frameworks such as DSCSA (Drug
Supply Chain Security Act), DEA controlled substance
requirements, FDA wholesale distribution rules, Florida
Board of Pharmacy regulations, inventory control,
diversion prevention, recordkeeping, and inspection
readiness.
.
, Exam Coverage
Drug supply chain security and traceability
requirements for prescription drugs
Detection and prevention of diversion, theft, and
counterfeit medications
Proper handling, storage, and environmental control
of pharmaceuticals
Recordkeeping standards for incoming and outgoing
drug shipments
Controlled substance handling, reporting, and
compliance requirements
Licensing obligations for wholesale distributors and
designated representatives
Recall procedures, quarantine processes, and product
returns management
Inspection readiness and regulatory audit response
procedures
Verification of product legitimacy and pedigree
documentation requirements
Temperature monitoring and cold-chain compliance
procedures
DEA and FDA regulatory enforcement expectations
, Shipping, receiving, and distribution documentation
accuracy
Handling of suspect or illegitimate drugs under
DSCSA rules
Security controls for warehouse and inventory
protection
Employee training and compliance responsibilities
Reporting obligations for theft or significant loss
Reverse distribution and destruction protocols
Supplier verification and transaction history
validation
Emergency procedures for compromised drug
products
Documentation retention timelines and audit trail
requirements
1.
A designated representative discovers missing controlled
substances during inventory reconciliation in a licensed
distribution warehouse. What is the most appropriate
immediate action?
A. Ignore minor shortages until next annual audit
, B. Adjust inventory records to match expected levels
C. Report the discrepancy to DEA and initiate
investigation procedures
D. Transfer responsibility to supplier immediately
Answer: C
Rationale: Controlled substance losses must be reported
promptly and investigated per federal and regulatory
requirements.
2.
A shipment of prescription drugs arrives without proper
pedigree documentation under DSCSA rules. What should
the distributor do first?
A. Store the shipment separately and sell later
B. Accept shipment conditionally with documentation
added later
C. Quarantine the shipment until verification is completed
D. Return immediately without inspection
Answer: C
Rationale: Suspect or undocumented drugs must be
quarantined until legitimacy is confirmed.
3.
REPRESENTATIVE EXAM (FLORIDA
BOARD OF PHARMACY – DESIGNATED
REPRESENTATIVE FOR PRESCRIPTION
DRUG DISTRIBUTORS ACTUAL EXAM
Certified Designated Representative (DR) – Florida
Prescription Drug Distributor Exam
The Florida Board of Pharmacy Certified Designated
Representative (DR) for Prescription Drug Distributors
examination evaluates competency in pharmaceutical
wholesale distribution compliance, focusing on federal and
Florida laws governing the safe storage, handling,
tracking, and distribution of prescription drugs. It
emphasizes regulatory frameworks such as DSCSA (Drug
Supply Chain Security Act), DEA controlled substance
requirements, FDA wholesale distribution rules, Florida
Board of Pharmacy regulations, inventory control,
diversion prevention, recordkeeping, and inspection
readiness.
.
, Exam Coverage
Drug supply chain security and traceability
requirements for prescription drugs
Detection and prevention of diversion, theft, and
counterfeit medications
Proper handling, storage, and environmental control
of pharmaceuticals
Recordkeeping standards for incoming and outgoing
drug shipments
Controlled substance handling, reporting, and
compliance requirements
Licensing obligations for wholesale distributors and
designated representatives
Recall procedures, quarantine processes, and product
returns management
Inspection readiness and regulatory audit response
procedures
Verification of product legitimacy and pedigree
documentation requirements
Temperature monitoring and cold-chain compliance
procedures
DEA and FDA regulatory enforcement expectations
, Shipping, receiving, and distribution documentation
accuracy
Handling of suspect or illegitimate drugs under
DSCSA rules
Security controls for warehouse and inventory
protection
Employee training and compliance responsibilities
Reporting obligations for theft or significant loss
Reverse distribution and destruction protocols
Supplier verification and transaction history
validation
Emergency procedures for compromised drug
products
Documentation retention timelines and audit trail
requirements
1.
A designated representative discovers missing controlled
substances during inventory reconciliation in a licensed
distribution warehouse. What is the most appropriate
immediate action?
A. Ignore minor shortages until next annual audit
, B. Adjust inventory records to match expected levels
C. Report the discrepancy to DEA and initiate
investigation procedures
D. Transfer responsibility to supplier immediately
Answer: C
Rationale: Controlled substance losses must be reported
promptly and investigated per federal and regulatory
requirements.
2.
A shipment of prescription drugs arrives without proper
pedigree documentation under DSCSA rules. What should
the distributor do first?
A. Store the shipment separately and sell later
B. Accept shipment conditionally with documentation
added later
C. Quarantine the shipment until verification is completed
D. Return immediately without inspection
Answer: C
Rationale: Suspect or undocumented drugs must be
quarantined until legitimacy is confirmed.
3.
